Beta Drugs Limited receives DCGI approval to launch Enzalutamide 160mg for treatment of prostate cancer

Beta Drugs Ltd (Adley Group) has received approval from the Drug Controller General of India (DCGI) to market Enzalutamide 160 mg under the brand name ADLEAP. This medicine was developed by the company to provide a much-needed treatment option for men with advanced prostate cancer. Prostate cancer is one of the most common cancers among men in India. The introduction of Enzalutamide 160 mg will make it easier for patients to take this medication, as previously patients had to take four tabs of 40 mg as per the approved dosage, resulting in better patient compliance, a lower risk of missed doses, and improved efficacy.

The introduction of Enzalutamide 160 mg is yet another milestone in the company's commitment to improving the lives of cancer patients through its extensive R&D capability and rapid release of NDDS formulations. By launching NDDS formulations and targeted therapies, the company hopes to maintain its growth momentum. Recently, the company launched the much-anticipated Palbociclib brand, 'ADCILIB,' which is a CDK 4/6 inhibitor indicated in breast cancer.

The company's in-house development of cancer drugs enables it to bridge the unmet need of cancer patients while also lowering the cost of therapy for Indian patients. Beta Drugs Ltd has a robust product pipeline and plans to introduce at least six new molecules or NDDS formulations in fiscal years 23-24.